Unfortunately, most clinical trials have been performed on patients with obesity, metabolic syndrome, and NAFLD, and only a few studies have explored and reported the beneficial efficacies of CB1R antagonists in the progression of hepatic steatosis, inflammation, and fibrosis.21,25 In fact, clinical trials of cannabinoid receptor inhibitors have not been carried out in patients with ALD owing to the side effects of the drugs. Here, CNR1 is linked to obesity due to melanocortin 4 receptor deficiency.